A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.
about
DeSigN: connecting gene expression with therapeutics for drug repurposing and developmentClinical Pharmacokinetics and Pharmacodynamics of Afatinib.Localisation Microscopy of Breast Epithelial ErbB-2 Receptors and Gap Junctions: Trafficking after γ-Irradiation, Neuregulin-1β, and Trastuzumab Application.Breast cancer treatment-induced cardiotoxicity.
P2860
A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
A phase II study of afatinib, ...... ncer progressing on letrozole.
@ast
A phase II study of afatinib, ...... ncer progressing on letrozole.
@en
type
label
A phase II study of afatinib, ...... ncer progressing on letrozole.
@ast
A phase II study of afatinib, ...... ncer progressing on letrozole.
@en
prefLabel
A phase II study of afatinib, ...... ncer progressing on letrozole.
@ast
A phase II study of afatinib, ...... ncer progressing on letrozole.
@en
P2093
P2860
P1433
P1476
A phase II study of afatinib, ...... ancer progressing on letrozole
@en
P2093
Guilhem Bousquet
Helene de Mont-Serrat
Jean-Louis Misset
Jean-Marc Ferrero
Joseph Gligorov
Katharina Gunzer
Katy Pelling
Martina Uttenreuther-Fischer
P2860
P2888
P356
10.1186/S40064-015-1601-7
P577
2016-01-19T00:00:00Z
P5875
P6179
1050022210